Floatz logo

Psma-Hbed-Cc

Metastatic Malignant Neoplasm in the Bone

Jonsson Comprehensive Cancer CenterradiopharmaceuticalPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Metastatic Malignant Neoplasm in the Bone cohort.

Asset / SponsorPhaseRating
Bms-907351
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 1/2B
Pembrolizumab
Mayo Clinic
Phase 1/2B
Nivolumab
National Cancer Institute (NCI)
Phase 3B
Epirubicin
Mayo Clinic
Phase 1/2B

View all 26 →

Same molecule, other indications

Psma-Hbed-Cc is also rated in:

Metastatic Prostate CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
Prostate AdenocarcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →